Antibodies Transformed
A revolutionary class of computationally designed biologics engineered to unlock challenging pathways and better treat disease
Antibodies Transformed
A revolutionary class of computationally designed biologics engineered to unlock challenging pathways and better treat disease
Structural Innovation Drives Therapeutic Opportunity
Archon Biosciences is a biotechnology company developing geometrically tunable protein therapeutics with differentiated distribution, engagement and function to target pathways other technologies cannot.
This new biologic class, the Antibody Cage (AbC), was invented with the science and technology recognized by the 2024 Nobel Prize in Chemistry at the Baker Lab in the Institute for Protein Design (IPD).
AbCs integrate the industry-proven binding affinity and specificity of antibodies with the power of generative protein design to create a range of molecules that have never existed before with new structures and functions.
AbCs are engineered with complete control over antibody orientation, binding domain valency, size, shape and rigidity.
SIZE & SHAPE
This structural control enables precise biodistribution and target engagement on cells to transform therapeutic effect.
AbCs Combine AI Design with Structural Control to Create Better Biologics
Archon turns previously intractable drug discovery challenges into engineering solutions by harnessing the structural and functional attributes of AbCs.
-
We leverage clinical, biological and structural data to identify key AbC design attributes and biological behaviors critical for therapeutic success.
-
We assemble AbCs across a wide range of geometric structures that exhibit tunable properties including: agonism, antagonism and preferential biodistribution.
-
We control and tune developability, manufacturability, immunogenicity, pharmacokinetics and other drug characteristics to quickly advance through preclinical development.
-
Our generative AI protein design platform creates a wide, tunable and rapidly iterative therapeutic and structural design space. AbCs are built from a geometric library that is unique across the industry.
Archon's AbC platform leverages geometric engineering to control biodistribution and engagement to unlock challenging therapeutic targets that other technologies cannot.
Our platform transforms Fc-based biologics into differentiated and more effective drugs. For business development and partnering inquiries, please email partner@archon.bio.